Flerie Invest AB has announced a mandatory bid to the shareholders of Toleranzia AB
Kurs & Likviditet
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Flerie Invest AB ("Flerie Invest") announced on 2 November 2022 that Flerie Invest has increased its holding in Toleranzia AB ("Toleranzia" or the "Company") to 30.4 per cent of the total number of shares and votes in the Company and that the threshold for mandatory bidding has thereby been passed in accordance with the Takeover Rules for certain trading platforms issued by the Swedish Corporate Governance Board (the "Takeover Rules"). In light of this, Flerie Invest has today announced a mandatory bid to the shareholders of Toleranzia (the "Bid").
Toleranzia's Board of Directors will evaluate Flerie Invest's Bid. Board member Thomas Eldered has a conflict of interest under section II.18 of the Takeover Rules and for that reason may not participate in the Board's consideration of matters related to the Offer.
In accordance with IV.3 Takeover Rules, the Board of Directors of Toleranzia will obtain a fairness opinion on the Bid from an independent expert. The Board of Directors will make public its opinion on the Bid and the reasons for its opinion, together with the valuation opinion, no later than two weeks before the expiry of the acceptance period.
For information on the Bid, please refer to Flerie Invest's website, www.flerie.com.
TOLERANZIA AB (PUBL)
Board of Directors
For further information, please contact:
Charlotte Fribert - CEO
Telephone: +46 763 19 98 98
E-mail: charlotte.fribert@toleranzia.se
About Toleranzia AB (publ)
Toleranzia AB (publ) develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can cure or significantly alleviate the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on the Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the Company's Certified Adviser.